Related Experiment Videos
Experience with live rubella virus vaccine combined with live vaccines against measles and mumps
Insights
Combined measles, mumps, and rubella vaccines offer a safe and effective way to increase immunization rates in young children. This trivalent vaccine simplifies the vaccination schedule, proving highly immunogenic and reducing disease incidence.
Area of Science:
- Immunology
- Virology
- Pediatric Infectious Diseases
Background:
- Childhood vaccination schedules are often burdened with multiple inoculations.
- This presents challenges for timely and complete immunization, particularly for diseases like mumps and rubella.
- Combined vaccines can streamline prophylaxis and improve coverage.
Purpose of the Study:
- To evaluate the safety, immunogenicity, and efficacy of a combined measles, mumps, and rubella (MMR) live vaccine.
- To determine if a single trivalent vaccine preparation can replace individual vaccinations.
Main Methods:
- Development and testing of combined live virus vaccine strains for measles (Leningrad-16), mumps (Leningrad-3), and rubella (Leningrad-8).
- Clinical trials involving subcutaneous administration of divalent or trivalent vaccine combinations to children aged 1-8 years.
- Assessment of serological conversion rates, antibody levels, and disease morbidity post-vaccination.
Main Results:
- Divalent and trivalent MMR vaccine combinations were found to be clinically harmless.
- The vaccines demonstrated high immunogenicity, inducing antibody levels comparable to monovalent vaccines.
- A single subcutaneous dose in children aged 1-8 years resulted in high seroconversion rates.
- Morbidity from measles, mumps, and rubella was reduced by over tenfold in children vaccinated with the trivalent vaccine.
Conclusions:
- Combined measles, mumps, and rubella vaccines are a valuable development for pediatric prophylaxis.
- The trivalent MMR vaccine is safe, highly immunogenic, and epidemiologically effective.
- This combined vaccine simplifies the immunization process, potentially increasing vaccination uptake and reducing disease burden.
Abstract:
Vaccination of pre-school children in the 1-7-years age-group for the specific prophylaxis of mumps and rubella is often difficult to arrange because of the already large number of inoculations given to these children. Combined vaccines to protect against measles, mumps and rubella should therefore be a valuable development. The existence of effective live vaccines for each of these 3 diseases makes possible the production of a single preparation suitable for subcutaneous inoculation.Tests on vaccine strains of measles (Leningrad-16), mumps (Leningrad-3) and rubella (Leningrad-8) viruses in various combinations have established that divalent or trivalent vaccines remain clinically harmless, highly immunogenic and epidemiologically effective. Single subcutaneous administrations of live measles vaccine combined with mumps or rubella vaccines or both, when given to children aged 1-8 years, brough about a high percentage of serological conversions and an increase in antibodies to a level comparable with that achieved with the corresponding monovalent vaccines. Morbidity from the 3 diseases was reduced among those vaccinated with the trivalent vaccine by 10 or more times, i.e., by about the same factor as when monovalent or divalent vaccines were used.